Literature DB >> 1997178

Induction of alpha-N-acetylgalactosamine-O-serine/threonine (Tn) antigen-mediated cellular immune response for active immunotherapy in mice.

A Singhal1, M Fohn, S Hakomori.   

Abstract

A block in carbohydrate chain elongation of O-glycosylated mucins results in accumulation of alpha-GalNAc O linked to serine or threonine (Tn antigen) in a large percentage of human adenocarcinomas. Immunization of mice with desialylated ovine submaxillary mucin (A-OSM), which contains a large concentration of Tn antigen, provided protection against challenge of a highly invasive Tn expressing syngeneic mouse mammary tumor, TA3-Ha. A similar protective effect was not observed in mice immunized with the deglycosylated mucin or irradiated TA3-Ha cells. Immunization with A-OSM but not with deglycosylated mucin resulted in high anti-Tn antibody response in mice. A-OSM induced in vitro proliferation of T-lymphocytes obtained from mice preimmunized with A-OSM or irradiated TA3-Ha cells. This antigen-specific T-cell response was significantly lower if lymphocytes were stimulated with either the deglycosylated or sialylated form of mucin. A-OSM stimulation induced primarily a CD4+ T-cell population, and these cells secreted interleukin 2 in a dose-dependent fashion. A-OSM was also able to induce delayed-type hypersensitivity in mice in response to footpad injections with irradiated TA3-Ha cells. These studies indicate that Tn antigen presented on a protein backbone is capable of providing cellular immunity and protection against tumor in mice.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1997178

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  25 in total

1.  Protein glycosylation in cancer biology: an overview.

Authors:  F Dall'olio
Journal:  Clin Mol Pathol       Date:  1996-06

Review 2.  Mucin glycoproteins in neoplasia.

Authors:  Y S Kim; J Gum; I Brockhausen
Journal:  Glycoconj J       Date:  1996-10       Impact factor: 2.916

3.  PD-1 Suppresses Development of Humoral Responses That Protect against Tn-Bearing Tumors.

Authors:  Marcela A Haro; Chad A Littrell; Zhaojun Yin; Xuefei Huang; Karen M Haas
Journal:  Cancer Immunol Res       Date:  2016-11-08       Impact factor: 11.151

Review 4.  Structure, biosynthesis, and function of salivary mucins.

Authors:  A M Wu; G Csako; A Herp
Journal:  Mol Cell Biochem       Date:  1994-08-17       Impact factor: 3.396

5.  Utilization of bench-stable and readily available nickel(II) triflate for access to 1,2-cis-2-aminoglycosides.

Authors:  Eric T Sletten; Sai Kumar Ramadugu; Hien M Nguyen
Journal:  Carbohydr Res       Date:  2016-10-24       Impact factor: 2.104

Review 6.  Cancer vaccines and carbohydrate epitopes.

Authors:  Jamie Heimburg-Molinaro; Michelle Lum; Geraldine Vijay; Miten Jain; Adel Almogren; Kate Rittenhouse-Olson
Journal:  Vaccine       Date:  2011-10-01       Impact factor: 3.641

7.  Polyclonal antibodies from patients immunized with a globo H-keyhole limpet hemocyanin vaccine: isolation, quantification, and characterization of immune responses by using totally synthetic immobilized tumor antigens.

Authors:  Z G Wang; L J Williams; X F Zhang; A Zatorski; V Kudryashov; G Ragupathi; M Spassova; W Bornmann; S F Slovin; H I Scher; P O Livingston; K O Lloyd; S J Danishefsky
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

8.  Broadly neutralizing antibodies targeted to mucin-type carbohydrate epitopes of human immunodeficiency virus.

Authors:  J E Hansen; C Nielsen; M Arendrup; S Olofsson; L Mathiesen; J O Nielsen; H Clausen
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

Review 9.  O-linked glycosylation in the mammary gland: changes that occur during malignancy.

Authors:  J M Burchell; A Mungul; J Taylor-Papadimitriou
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-07       Impact factor: 2.673

Review 10.  Traveling for the glycosphingolipid path.

Authors:  S Hakomori
Journal:  Glycoconj J       Date:  2000 Jul-Sep       Impact factor: 2.916

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.